MCM2 and non-small cell lung carcinoma: Given that MCM2 and MCM4 not only constantly showed association with the clinical stages and OS, but also exhibited the highest mutation rate in LUAD and LUSC patients, respectively, we then set out to validate the overexpression of MCM2 and MCM4 in NSCLC tissues.